The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

parC  -  DNA topoisomerase IV subunit A

Escherichia coli O157:H7 str. EDL933

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of parC


High impact information on parC

  • Of 149 isolates, 102 (68.5%) had a MIC > or = 8 microg/mL, 138 (92.6%) had > or = 1 gyrA mutation, 101 (67.8%) had > or = 1 parC mutation, and 59 (39.6%) demonstrated OST [2].
  • With S. aureus, the dimer selected spontaneous resistant gyrA mutants, whereas ciprofloxacin selected a parC mutant [1].

Biological context of parC


Associations of parC with chemical compounds

  • RESULTS: The dimer was lethal, in some cases exhibiting more activity than ciprofloxacin (particularly with wild-type cells and a parC mutant of S. aureus) [1].
  • The objective of this study was to analyse an array of ciprofloxacin and norfloxacin derivatives in order to determine those with good activity against bacteria that already present fluoroquinolone resistance associated with mutations in the gyrA and/or parC genes [5].


  1. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. Zhao, X., Quinn, B., Kerns, R., Drlica, K. J. Antimicrob. Chemother. (2006) [Pubmed]
  2. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative. Lautenbach, E., Fishman, N.O., Metlay, J.P., Mao, X., Bilker, W.B., Tolomeo, P., Nachamkin, I. J. Infect. Dis. (2006) [Pubmed]
  3. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa. Pasquali, F., Manfreda, G. Vet. Microbiol. (2007) [Pubmed]
  4. Vertical transmission of a fluoroquinolone-resistant Escherichia coli within an integrated broiler operation. Petersen, A., Christensen, J.P., Kuhnert, P., Bisgaard, M., Olsen, J.E. Vet. Microbiol. (2006) [Pubmed]
  5. Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria. Vila, J., Sánchez-Céspedes, J., Sierra, J.M., Piqueras, M., Nicolás, E., Freixas, J., Giralt, E. Int. J. Antimicrob. Agents (2006) [Pubmed]
WikiGenes - Universities